argenx (NASDAQ:ARGX – Free Report) had its price target hoisted by Jefferies Financial Group from $497.00 to $513.00 in a research report report published on Monday morning, FlyOnTheWall reports.
A number of other research firms also recently weighed in on ARGX. Bank of America lifted their price objective on argenx from $444.00 to $446.00 in a report on Friday, May 5th. Citigroup initiated coverage on argenx in a report on Tuesday, April 25th. They set a buy rating and a $450.00 price objective on the stock. JMP Securities cut their target price on shares of argenx from $448.00 to $445.00 in a research note on Friday, May 5th. Societe Generale initiated coverage on shares of argenx in a research note on Thursday, June 15th. They issued a sell rating for the company. Finally, Wedbush reiterated an outperform rating and issued a $432.00 target price on shares of argenx in a research note on Friday, April 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $463.70.
argenx Stock Performance
argenx stock opened at $484.43 on Monday. The business’s 50-day simple moving average is $397.12 and its 200-day simple moving average is $382.69. The firm has a market capitalization of $27.11 billion, a PE ratio of -52.15 and a beta of 0.72. argenx has a 52 week low of $333.07 and a 52 week high of $498.63.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. KB Financial Partners LLC increased its position in shares of argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 45 shares in the last quarter. CI Investments Inc. increased its position in shares of argenx by 202.6% in the 4th quarter. CI Investments Inc. now owns 79 shares of the company’s stock valued at $30,000 after buying an additional 156 shares in the last quarter. Toronto Dominion Bank bought a new stake in shares of argenx in the 1st quarter valued at $36,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of argenx in the 4th quarter valued at $37,000. Finally, Ronald Blue Trust Inc. increased its position in shares of argenx by 728.6% in the 4th quarter. Ronald Blue Trust Inc. now owns 116 shares of the company’s stock valued at $41,000 after buying an additional 102 shares in the last quarter. Institutional investors and hedge funds own 55.90% of the company’s stock.
argenx Company Profile
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.
Featured Articles
- Five stocks we like better than argenx
- Is It Time To Take Another Bite Of Chewy, Inc?
- GreenPower Motor Company Shifts Into High Gear
- Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
- Can Unity Software Sustain The Momentum?
- Nvidia Invested $50 million into This AI Drug Discovery Biotech
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.
